Overview

• The peer-reviewed follow-up, published Sept. 4 in the Journal of Psychedelic Studies, revisited 24 adults from a 2021 trial that paired two psilocybin sessions with about 13 hours of psychotherapy.
• At the five-year mark, 67% were in remission, edging up from 58% at one year, with nonparticipants conservatively counted as relapsed.
• Eighteen of the original 24 completed follow-up assessments, and the analysis assumed the six nonparticipants returned to pre-treatment levels.
• Most participants reported additional treatments over the interval, including antidepressants, psychotherapy, ketamine, or self-directed psychedelic use.
• Interviews described durable gains in functioning and positive affect, emphasized the value of a strong therapeutic relationship, and noted few long-term adverse effects.